Investment Thesis
Accustem Sciences is in severe financial distress with negative stockholders' equity of -$2.9M, indicating the company is technically insolvent. The company is burning cash at an unsustainable rate (-$883.7K free cash flow) with only $14.4K in cash reserves against $4.5M in liabilities. With zero revenue, no viable path to profitability, and complete lack of operating metrics, the company faces imminent financial collapse.
Strengths
Risks
- Negative stockholders' equity of -$2.9M indicates insolvency
- Critically low cash balance of $14.4K with $4.5M in liabilities
- No revenue generation; company is pre-revenue or revenue-less
- Negative free cash flow of -$883.7K burning through minimal cash reserves
- Current ratio of 0.35x indicates severe liquidity crisis and inability to meet short-term obligations
- No insider activity or buying support in last 90 days
- Operating losses of -$1.2M with no offsetting revenue
- Negative ROA of -78.9% indicates catastrophic asset inefficiency
Key Metrics to Watch
- Cash burn rate and runway to insolvency
- Revenue inception and pathway to profitability
- Debt restructuring or equity injection announcements
- Changes in stockholders' equity trajectory
Financial Metrics
Revenue
N/A
Net Income
-1.2M
EPS (Diluted)
$-0.08
Free Cash Flow
-883.7K
Total Assets
1.6M
Cash
14.4K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-78.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.35x
Quick Ratio
0.35x
Debt/Equity
N/A
Debt/Assets
285.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T11:32:10.097025 |
Data as of: 2025-09-30 |
Powered by Claude AI